No Detail Found!

Unlocking the potential: exploring the gut microbiome's ability to absorb the antihypertensive Enalapril

Author(s)
Saima Malik Health Biology Research Lab (HBRL), Department of Physiology, Government College University,Faisalabad,Pakistan
Imran Mukhtar Health Biology Research Lab (HBRL), Department of Physiology, Government College University,Faisalabad,Pakistan
Humaira Muzaffar Health Biology Research Lab (HBRL), Department of Physiology, Government College University,Faisalabad,Pakistan
Laaraib Nawaz Health Biology Research Lab (HBRL), Department of Physiology, Government College University,Faisalabad,Pakistan
Haseeb Anwar Health Biology Research Lab (HBRL), Department of Physiology, Government College University,Faisalabad,Pakistan
Abstract
The gut microbiome potentially modulates pharmacokinetics of orally administered drugs. Homologous transporting proteins in epical membrane of the enterocytes and cell membrane of the residing microbial cells of the host may compete for absorption of the orally administered drugs. Microbial cells residing the small intestine of the host may uptake/bio-accumulate some of the quantity of the dose of orally administered drug. This project is aimed to observe absorption/bio-accumulation behavior of enalapril by the gut microbiome when enalapril was administered orally in pure form and in the presence of excipients (Tablet; commercial preparation). Currently, no data confirms specific transport system for enalapril uptake by gut microbiome in absence and presence of excipients as well. Two in-vivo trials, enalapril pure drug treated trial and enalapril commercial tablet treated trial were conducted in parallel. Each trial was conducted in adult Wistar albino rats (n=42) divided into seven groups having same number of rats in each group (n=6); one control group and six drug treated groups administered orally with single dose of enalapril 10mg/kgbwt. Rats (n=6) were subsequently sacrificed at different intestinal transit times of 1, 2, 3, 4, 5 and 6 hours post drug administration to harvest microbial mass pellet from digesta. Pellet was lysed to expose microbial lysate and pursued through HPLC. The microbiome absorbed enalapril at 4hour transit time (103±7.31µg) significantly (p=0.05) higher as compared to 5hour transit time (73.2±5.17µg). Percent dose recovery from microbiome was significantly (p=0.05) higher at 4hour transit time (4.15±0.05%) as compared to 5hour transit time (3.14±0.18%) post drug administration. Independent of presence of excipients, from both formulations enalapril was absorbed in equal amount competitively by the intestinal microbiome through the homologous transport mechanism present in the enterocytes of the host. Conclusively, enalapril serves as a substrate of gut microbiome independent of dosage form when administered orally.
Publication Details
Page(s) 1-14
Published Journal: Asian Journal of Agriculture and Biology, Volume: 1, Issue: 0, Year: 2025

Request the full text from PASTIC

Keywords
Percent drug recovery, Microbial lysate, Enalapril, microbiome
References
Anwar H,Mukhtar I,Muzaffar H,Irfan S,Saleem S,Ijaz F,Akash MSH F .2024 .. , : 25-50.
Averina OV,Poluektova EU,Marsova MV,Danilenko VN .2021 .Biomarkers and utility of the antioxidant potential of probiotic Lactobacilli and Bifidobacteria as representatives of the human gut microbiota. Biomedicines, 9(10) : 1340.
Biegel A,Knütter I,Hartrodt B,Gebauer S,Theis S,Luckner P .2006 .The renal type H+/peptide symporter PEPT2: structure-affinity relationships. Amino acids, 31 : 137-56.
Brandsch M,Knütter I,Bosse‐Doenecke E .2008 .Pharmaceutical and pharmacological importance of peptide transporters. J. Pharm. Pharmacol, 60(5) : 543-585.
Bu G,Parrish S,Gleason PR,Nielsen DR,Nannenga BL .2020 .Heterologous expression and purification of the bicarbonate transporter BicA from Synechocystis sp. PCC 6803. Protein Expr. Purif, 175 : 105716.
CambridgeSoft .1986 .CambridgeSoft Corp. ChemDraw Ultra 12.0, 0(Copyright) : .
Chen HQ,Gong JY,Xing K,Liu MZ,Ren H,Luo JQ .2022 .Pharmacomicrobiomics: exploiting the drug-microbiota interactions in antihypertensive treatment. Front. Med, 8 : 742394.
Coker O .2023 .Non-bacteria microbiome (virus, fungi, and archaea. gastrointestinal cancer, : 91-106.
Colella M,Charitos IA,Ballini A,Cafiero C,Topi S,Palmirotta R,Santacroce L .2023 .Microbiota revolution: How gut microbes regulate our lives. WJG, 29(28) : 4368.
Coniglio MV,Luna MJ,Provensal P,Watson S,Ortiz ME,Ludueña HR,Magnoli AP .2023 .The Impact of Saccharomyces cerevisiae var. Boulardii RC009 on productive parameters in weaned calves and cull cows. ABRs, 13 : 1-6.
Di Pierro F .2021 .Gut microbiota parameters potentially useful in clinical perspective. Microorganisms, 9(11) : 2402.
Demishtein K,Reifen R,Shemesh M .2019 .Antimicrobial properties of magnesium open opportunities to develop healthier food. Nutrients, 11(10) : 2363.
Dobson PD,Kell DB .2008 .Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule?. Nat. Rev. Drug Discov, 7(3) : 205-20.
Doestzada M,Vila AV,Zhernakova A,Koonen DP,Weersma RK,Touw DJ,Kuipers F,Wijmenga C,Fu J .2018 .Pharmacomicrobiomics: a novel route towards personalized medicine?. Protein Cell, 9(5) : 432-445.
Eberhardt J,Santos-Martins D,Tillack AF,Forli S .2021 .New docking methods, expanded force field, and python bindings. J. Chem. Inf. Model, 61(8) : 3891-3898.
Effinger A,O'Driscoll CM,McAllister M,Fotaki N .2019 .Impact of gastrointestinal disease states on oral drug absorptionimplications for formulation design-a PEARRL review. J. Pharm. Pharmacol, 71(4) : 674-698.
Ekici S,Demirci M,Dülger D,Yiğin A .2023 .The Quinolone Resistance Genes in the Bacteriophage DNA Fractions in the Healthy Calf Stool Samples Via qPCR. Kafkas Univ. Vet, 29(1) : 49-54.
El Aidy S,Van Den Bogert B and Kleerebezem M .2015 .The small intestine microbiota, nutritional modulation and relevance for health. Curr. Opin. Biotechnol, 32 : 14-20.
Hollister EB,Gao C,Versalovic J .2014 .Compositional and functional features of the gastrointestinal microbiome and their effects on human health. J. Gastroenterol, 146(6) : 1449-58.
Fei YJ,Sugawara M,Liu JC,Li H.,Ganapathy V,Ganapathy ME,Leibach FH .2000 .cDNA structure, genomic organization, and promoter analysis of the mouse intestinal peptide transporter PEPT1. Biochim. Biophys. Acta Gene Struct. Expression, 1492(1) : 145-154.
Ferreira LG,Dos Santos RN,Oliva G,Andricopulo AD .2015 .Molecular docking and structure-based drug design strategies. Molecules, 20(7) : 13384-13421.
Gao K,Wang PX,Mei X,Yang T,Yu K .2024 .Untapped potential of gut microbiome for hypertension management. Gut Microbes, 16(1) : 2356278.
Goh EB,Siino DF,Igo MM .2004 .The Escherichia coli tppB (ydgR) gene represents a new class of OmpR-regulated genes. J. Bacteriol, 186(12) : 4019-24.
Gu S,Chen D,Zhang J-N,Lv X,Wang K,Duan L-P .2013 .Bacterial community mapping of the mouse gastrointestinal tract. PloS one, 8(10) : e74957.
Harder D,Stolz J,Casagrande F,Obrdlik P,Weitz D,Fotiadis D .2008 .DtpB (YhiP) and DtpA (TppB, YdgR) are prototypical proton‐dependent peptide transporters of Escherichia coli. The FEBS J, 275(13) : 3290-8.
Jackson R and Bellamy M .2015 .Antihypertensive drugs. BJA Education, 15(6) : 280-5.
Jóźwiak-Bebenista M,Nowak JZ .2014 .Paracetamol: mechanism of action, applications and safety concern. Acta Pol. Pharm, 71(1) : 11-23.
Li D,Chen H,Mao B,Yang Q,Zhao J,Gu Z .2017 .Microbial biogeography and core microbiota of the rat digestive tract. Sci. Rep, 7(1) : 1-16.
Lorca GL,Barabote RD,Zlotopolski V,Tran C,Winnen B,Hvorup RN,Stonestrom AJ,Nguyen E,Huang LW,Kim DS,Saier MH .2007 .Transport capabilities of eleven gram-positive bacteria: comparative genomic analyses. Biochim. Biophys. Acta Biomembr, 1768(6) : 1342-66.
Maier L,Pruteanu M,Kuhn M,Zeller G,Telzerow A,Anderson EE .2018 .Extensive impact of non-antibiotic drugs on human gut bacteria. Nature, 10 : 623-8.
Morrison RA,Chong S,Marino AM,Wasserman MA,Timmins P,Moore VA .1996 .Suitability of enalapril as a probe of the dipeptide transporter system: in vitro and in vivo studies. J. Pharm. Res, 13 : 1078-82.
Morris GM,Huey R,Lindstrom W,Sanner MF,Belew RK,Goodsell DS,Olson AJ .2009 .AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem, 30(16) : 2785-2791.
Mukhtar I,Anwar H,Hussain G,Rasul A,Naqvi SAR,Faisal MN,Mustafa I,Malik S,Shaukat A,Mirza OA,Sohail MU .2019 .Detection of Paracetamol as substrate of the gut microbiome. PJPS, 32(2) : 751-757.
Mukhtar I,Anwar H,Iftikhar A,Hashem HE,Ali Q,Siddique F .2022 .Human targeted phenobarbital presents a poor substrate of gut microbiome deciphering new drug targets beyond pharmacokinetic curbs. BMC Pharmacol. Toxicol, 23(1) : 85.
Mussap M,Loddo C,Fanni C,Fanos V .2020 .Metabolomics in pharmacology-a delve into the novel field of pharmacometabolomics. Expert Rev. Clin. Pharmacol, 13(2) : 115-134.
Nielsen CU,Brodin B,Jørgensen FS,Frokjaer S,Steffansen B .2002 .Human peptide transporters: therapeutic applications. Expert Opin. Ther. Pat, 12(9) : 1329-1350.
Nikaido H .2003 .Molecular basis of bacterial outer membrane permeability revisited. J. Mol. Biol, 67(4) : 593-656.
Pizzagalli MD,Bensimon A,Superti‐Furga G .2021 .A guide to plasma membrane solute carrier proteins. The FEBS J, 288(9) : 2784-2835.
Prabhala BK,Aduri NG,Iqbal M,Rahman M,Gajhede M,Hansen PR .2017 .Several hPepT1- transported drugs are substrates of the Escherichia coli proton-coupled oligopeptide transporter YdgR. Microbiol. Res, 168(5) : 443-9.
Rubio-Aliaga I,Daniel H .2008 .Peptide transporters and their roles in physiological processes and drug disposition. Xenobiotica, 38(7-8) : 1022-42.
Stojančević M,Bojić G,Al Salami H and Mikov M .2014 .The influence of intestinal tract and probiotics on the fate of orally administered drugs. Curr. Iss Mol. Biol, 16(1) : 55-68.
Subramaniam S,Kamath S,Ariaee A,Prestidge C,Joyce P .2023 .The impact of common pharmaceutical excipients on the gut microbiota. Expert. Opin. Drug. Deliv, 20(10) : 1297-1314.
Sultana N,Naveed S,Arayne MS,Med R&R .2013 .Monitoring of in vitro interaction studies of enalapril with hypoglycemic agents by LC-UV. Chem, 3 : 19-29.
Torres-Carrillo N,Martínez-López E,Torres-Carrillo NM,López-Quintero A,Moreno- Ortiz JM,González-Mercado A,Gutiérrez-Hurtado IA .2023 .Pharmacomicrobiomics and DrugInfection Interactions: The Impact of Commensal, Symbiotic and Pathogenic Microorganisms on a Host Response to Drug Therapy. Int. J. Mol. Sci, 24(23) : 17100.
Urttiac A,Sadée W,Johns SJ .2001 .Genomic structure of proton-coupled oligopeptide transporter hPEPT1 and pH-sensing regulatory splice variant. AAPS PharmSciTech, 3(1) : 66-79.
Visualizer DS .2005 .. Accelrys Software Inc, : .
Yusuf D,Davis AM,Kleywegt GJ,Schmitt S .2008 .An alternative method for the evaluation of docking performance: RSR vs RMSD. J. Chem. Inf. Model, 48(7) : 1411-1422.
Zentgraf M,Steuber H,Koch C,La Motta C,Sartini S,Sotriffer CA,Klebe G .2009 .How reliable are current docking approaches for structurebased drug design? Lessons from aldose reductase. Angew. Chem, 46(19) : 3575-3578.
0

Citations

0

Downloads

9

Views